{"id":"https://openalex.org/W4284669148","doi":"https://doi.org/10.1136/jitc-2022-004610","title":"Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma","display_name":"Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma","publication_year":2022,"publication_date":"2022-07-01","ids":{"openalex":"https://openalex.org/W4284669148","doi":"https://doi.org/10.1136/jitc-2022-004610","pmid":"https://pubmed.ncbi.nlm.nih.gov/35798536","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/9263926"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2022-004610","doi":"https://doi.org/10.1136/jitc-2022-004610","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-004610","pdf_url":"https://jitc.bmj.com/content/jitc/10/7/e004610.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for ImmunoTherapy of Cancer","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","datacite","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/jitc/10/7/e004610.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5059961435","display_name":"In\u00eas Pires da Silva","orcid":"https://orcid.org/0000-0003-3540-8906","observed_orcids":["https://orcid.org/0000-0003-3540-8906"]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]},{"id":"https://openalex.org/I2803024705","display_name":"Westmead Hospital","ror":"https://ror.org/04gp5yv64","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2803024705","https://openalex.org/I4405259172"]},{"id":"https://openalex.org/I4210118383","display_name":"Melanoma Institute Australia","ror":"https://ror.org/02jxrhq31","country_code":"AU","type":"nonprofit","lineage":["https://openalex.org/I4210118383"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Ines Pires da Silva","raw_affiliation_strings":["Blacktown & Westmead Hospital, Sydney, New South Wales, Australia","Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia","Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia"],"raw_orcid":"https://orcid.org/0000-0003-3540-8906","affiliations":[{"raw_affiliation_string":"Blacktown & Westmead Hospital, Sydney, New South Wales, Australia","institution_ids":["https://openalex.org/I2803024705"]},{"raw_affiliation_string":"Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia","institution_ids":["https://openalex.org/I129604602"]},{"raw_affiliation_string":"Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia","institution_ids":["https://openalex.org/I129604602","https://openalex.org/I4210118383"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080146348","display_name":"Danny Zakria","orcid":"https://orcid.org/0000-0001-8399-5311","observed_orcids":["https://orcid.org/0000-0001-8399-5311"]},"institutions":[{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Danny Zakria","raw_affiliation_strings":["Vanderbilt University Medical Center, Nashville, Tennessee, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University Medical Center, Nashville, Tennessee, USA","institution_ids":["https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036987287","display_name":"Tasnia Ahmed","orcid":"https://orcid.org/0000-0001-7969-6335","observed_orcids":["https://orcid.org/0000-0001-7969-6335"]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]},{"id":"https://openalex.org/I4210118383","display_name":"Melanoma Institute Australia","ror":"https://ror.org/02jxrhq31","country_code":"AU","type":"nonprofit","lineage":["https://openalex.org/I4210118383"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Tasnia Ahmed","raw_affiliation_strings":["Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia","institution_ids":["https://openalex.org/I129604602","https://openalex.org/I4210118383"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090080848","display_name":"Claudia Trojanello","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210141868","display_name":"Istituto Nazionale Tumori IRCCS \"Fondazione G. Pascale\"","ror":"https://ror.org/0506y2b23","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210141868","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Claudia Trojanello","raw_affiliation_strings":["Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy","institution_ids":["https://openalex.org/I4210141868"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008364803","display_name":"Florentia Dimitriou","orcid":"https://orcid.org/0000-0003-4529-3372","observed_orcids":["https://orcid.org/0000-0003-4529-3372"]},"institutions":[{"id":"https://openalex.org/I4210100468","display_name":"University Hospital Zurich","ror":"https://ror.org/01462r250","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210100468"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Florentia Dimitriou","raw_affiliation_strings":["Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland","institution_ids":["https://openalex.org/I4210100468"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065819179","display_name":"Clara Allayous","orcid":"https://orcid.org/0000-0002-1762-152X","observed_orcids":["https://orcid.org/0000-0002-1762-152X"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]},{"id":"https://openalex.org/I4210144610","display_name":"H\u00f4pital Saint-Louis","ror":"https://ror.org/049am9t04","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210144610"]},{"id":"https://openalex.org/I4387154437","display_name":"HIPI -  Immunologie humaine, physiopathologie et immunith\u00e9rapie","ror":"https://ror.org/008e1sp22","country_code":"FR","type":"facility","lineage":["https://openalex.org/I154526488","https://openalex.org/I204730241","https://openalex.org/I4387154437"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Clara Allayous","raw_affiliation_strings":["Dermatolo-Oncology AP-HP H\u00f4pital Saint-Louis, INSERM U976, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dermatolo-Oncology AP-HP H\u00f4pital Saint-Louis, INSERM U976, Paris, France","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210097159","https://openalex.org/I4210144610","https://openalex.org/I4387154437"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050031536","display_name":"Camille Lea Gerard","orcid":"https://orcid.org/0000-0002-6007-1746","observed_orcids":["https://orcid.org/0000-0002-6007-1746"]},"institutions":[{"id":"https://openalex.org/I2802229882","display_name":"Centre Hospitalier Universitaire Vaudois","ror":"https://ror.org/05a353079","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I2802229882"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Camille Gerard","raw_affiliation_strings":["Precision Oncology Centre, CHUV, Lausanne, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Precision Oncology Centre, CHUV, Lausanne, Switzerland","institution_ids":["https://openalex.org/I2802229882"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064923908","display_name":"Lisa Zimmer","orcid":"https://orcid.org/0000-0002-3680-3521","observed_orcids":["https://orcid.org/0000-0002-3680-3521"]},"institutions":[{"id":"https://openalex.org/I4210119759","display_name":"Essen University Hospital","ror":"https://ror.org/02na8dn90","country_code":"DE","type":"funder","lineage":["https://openalex.org/I4210119759"]},{"id":"https://openalex.org/I62318514","display_name":"University of Duisburg-Essen","ror":"https://ror.org/04mz5ra38","country_code":"DE","type":"education","lineage":["https://openalex.org/I62318514"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Lisa Zimmer","raw_affiliation_strings":["Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany","institution_ids":["https://openalex.org/I4210119759","https://openalex.org/I62318514"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040969461","display_name":"Serigne Lo","orcid":"https://orcid.org/0000-0001-5092-5544","observed_orcids":["https://orcid.org/0000-0001-5092-5544"]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]},{"id":"https://openalex.org/I4210118383","display_name":"Melanoma Institute Australia","ror":"https://ror.org/02jxrhq31","country_code":"AU","type":"nonprofit","lineage":["https://openalex.org/I4210118383"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Serigne Lo","raw_affiliation_strings":["Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia"],"raw_orcid":"https://orcid.org/0000-0001-5092-5544","affiliations":[{"raw_affiliation_string":"Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia","institution_ids":["https://openalex.org/I129604602","https://openalex.org/I4210118383"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009968141","display_name":"Olivier Alain Michielin","orcid":"https://orcid.org/0000-0003-4926-6355","observed_orcids":["https://orcid.org/0000-0003-4926-6355"]},"institutions":[{"id":"https://openalex.org/I2802229882","display_name":"Centre Hospitalier Universitaire Vaudois","ror":"https://ror.org/05a353079","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I2802229882"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Olivier Michielin","raw_affiliation_strings":["Precision Oncology Centre, CHUV, Lausanne, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Precision Oncology Centre, CHUV, Lausanne, Switzerland","institution_ids":["https://openalex.org/I2802229882"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025478490","display_name":"C\u00e9l\u00e8ste Lebb\u00e9","orcid":"https://orcid.org/0000-0002-5854-7290","observed_orcids":["https://orcid.org/0000-0002-5854-7290"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I204730241","display_name":"Universit\u00e9 Paris Cit\u00e9","ror":"https://ror.org/05f82e368","country_code":"FR","type":"education","lineage":["https://openalex.org/I204730241"]},{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]},{"id":"https://openalex.org/I4210144610","display_name":"H\u00f4pital Saint-Louis","ror":"https://ror.org/049am9t04","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210144610"]},{"id":"https://openalex.org/I4387154437","display_name":"HIPI -  Immunologie humaine, physiopathologie et immunith\u00e9rapie","ror":"https://ror.org/008e1sp22","country_code":"FR","type":"facility","lineage":["https://openalex.org/I154526488","https://openalex.org/I204730241","https://openalex.org/I4387154437"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Celeste Lebbe","raw_affiliation_strings":["Universit\u00e9 Paris Cite, Dermatolo-Oncology AP-HP H\u00f4pital Saint-Louis, INSERM U976, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universit\u00e9 Paris Cite, Dermatolo-Oncology AP-HP H\u00f4pital Saint-Louis, INSERM U976, Paris, France","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I204730241","https://openalex.org/I4210097159","https://openalex.org/I4210144610","https://openalex.org/I4387154437"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082278497","display_name":"Joanna Mangana","orcid":"https://orcid.org/0000-0003-3962-7575","observed_orcids":["https://orcid.org/0000-0003-3962-7575"]},"institutions":[{"id":"https://openalex.org/I4210100468","display_name":"University Hospital Zurich","ror":"https://ror.org/01462r250","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210100468"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Johanna Mangana","raw_affiliation_strings":["Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland","institution_ids":["https://openalex.org/I4210100468"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029398339","display_name":"Paolo A. Ascierto","orcid":"https://orcid.org/0000-0002-8322-475X","observed_orcids":["https://orcid.org/0000-0002-8322-475X"]},"institutions":[{"id":"https://openalex.org/I4210141868","display_name":"Istituto Nazionale Tumori IRCCS \"Fondazione G. Pascale\"","ror":"https://ror.org/0506y2b23","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210141868","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Paolo Antonio Ascierto","raw_affiliation_strings":["Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy"],"raw_orcid":"https://orcid.org/0000-0002-8322-475X","affiliations":[{"raw_affiliation_string":"Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy","institution_ids":["https://openalex.org/I4210141868"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025067315","display_name":"Douglas Buckner Johnson","orcid":"https://orcid.org/0000-0002-6390-773X","observed_orcids":["https://orcid.org/0000-0002-6390-773X"]},"institutions":[{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas B Johnson","raw_affiliation_strings":["Vanderbilt University Medical Center, Nashville, Tennessee, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University Medical Center, Nashville, Tennessee, USA","institution_ids":["https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083061830","display_name":"Matteo Salvatore Carlino","orcid":"https://orcid.org/0000-0002-7861-4104","observed_orcids":["https://orcid.org/0000-0002-7861-4104"]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]},{"id":"https://openalex.org/I2803024705","display_name":"Westmead Hospital","ror":"https://ror.org/04gp5yv64","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2803024705","https://openalex.org/I4405259172"]},{"id":"https://openalex.org/I4210118383","display_name":"Melanoma Institute Australia","ror":"https://ror.org/02jxrhq31","country_code":"AU","type":"nonprofit","lineage":["https://openalex.org/I4210118383"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Matteo Carlino","raw_affiliation_strings":["Blacktown & Westmead Hospital, Sydney, New South Wales, Australia","Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Blacktown & Westmead Hospital, Sydney, New South Wales, Australia","institution_ids":["https://openalex.org/I2803024705"]},{"raw_affiliation_string":"Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia","institution_ids":["https://openalex.org/I129604602","https://openalex.org/I4210118383"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022520811","display_name":"Alexander Maxwell Menzies","orcid":"https://orcid.org/0000-0001-5183-7562","observed_orcids":["https://orcid.org/0000-0001-5183-7562"]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]},{"id":"https://openalex.org/I2800079252","display_name":"Royal North Shore Hospital","ror":"https://ror.org/02gs2e959","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800079252"]},{"id":"https://openalex.org/I4210118383","display_name":"Melanoma Institute Australia","ror":"https://ror.org/02jxrhq31","country_code":"AU","type":"nonprofit","lineage":["https://openalex.org/I4210118383"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Alexander Menzies","raw_affiliation_strings":["Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia","Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia","Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia","institution_ids":["https://openalex.org/I129604602"]},{"raw_affiliation_string":"Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia","institution_ids":["https://openalex.org/I129604602","https://openalex.org/I4210118383"]},{"raw_affiliation_string":"Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia","institution_ids":["https://openalex.org/I2800079252"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5070576000","display_name":"Georgina Venetia Long","orcid":"https://orcid.org/0000-0001-8894-3545","observed_orcids":["https://orcid.org/0000-0001-8894-3545"]},"institutions":[{"id":"https://openalex.org/I129604602","display_name":"The University of Sydney","ror":"https://ror.org/0384j8v12","country_code":"AU","type":"education","lineage":["https://openalex.org/I129604602"]},{"id":"https://openalex.org/I2800079252","display_name":"Royal North Shore Hospital","ror":"https://ror.org/02gs2e959","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800079252"]},{"id":"https://openalex.org/I4210118383","display_name":"Melanoma Institute Australia","ror":"https://ror.org/02jxrhq31","country_code":"AU","type":"nonprofit","lineage":["https://openalex.org/I4210118383"]}],"countries":["AU"],"is_corresponding":true,"raw_author_name":"Georgina Long","raw_affiliation_strings":["Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia","Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia","Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia","institution_ids":["https://openalex.org/I129604602"]},{"raw_affiliation_string":"Melanoma Institute Australia, The University of Sydney, North Sydney, New South Wales, Australia","institution_ids":["https://openalex.org/I129604602","https://openalex.org/I4210118383"]},{"raw_affiliation_string":"Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia","institution_ids":["https://openalex.org/I2800079252"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":15,"corresponding_author_ids":["https://openalex.org/A5070576000"],"corresponding_institution_ids":["https://openalex.org/I129604602","https://openalex.org/I2800079252","https://openalex.org/I4210118383"],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":1.5498,"has_fulltext":true,"cited_by_count":20,"citation_normalized_percentile":{"value":0.82978365,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"10","issue":"7","first_page":"e004610","last_page":"e004610"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.7544000148773193,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.7544000148773193,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.23600000143051147,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.002199999988079071,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.7720000147819519},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":0.9789999723434448},{"id":"https://openalex.org/keywords/braf-v600e-mutation","display_name":"BRAF V600E mutation","score":0.6930000185966492},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9309999942779541},{"id":"https://openalex.org/keywords/braf-mek-inhibitors","display_name":"BRAF/MEK inhibitors","score":0.9350000023841858},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.6349999904632568},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.7110000252723694},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6549999713897705},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8140000104904175},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.9190000295639038},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.640999972820282},{"id":"https://openalex.org/keywords/brain-metastases","display_name":"brain metastases","score":0.6349999904632568},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.5910000205039978},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-related-pneumonitis","display_name":"immune-related pneumonitis","score":0.5139999985694885},{"id":"https://openalex.org/keywords/immune-mediated-colitis","display_name":"immune-related colitis","score":0.6679999828338623},{"id":"https://openalex.org/keywords/immune-related-endocrinopathy","display_name":"immune-related endocrinopathy","score":0.625}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8962990045547485},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.7521064877510071},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6504466533660889},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.621852457523346},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5818628072738647},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5129365921020508},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.4274429380893707},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.2322787046432495},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.23204612731933594},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2018854320049286},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.0},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000096142","descriptor_name":"Cutaneous Malignant Melanoma","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001932","descriptor_name":"Brain Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D016609","descriptor_name":"Neoplasms, Second Primary","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D020929","descriptor_name":"Mitogen-Activated Protein Kinase Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false}],"locations_count":10,"locations":[{"id":"doi:10.1136/jitc-2022-004610","doi":"https://doi.org/10.1136/jitc-2022-004610","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-004610","pdf_url":"https://jitc.bmj.com/content/jitc/10/7/e004610.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for ImmunoTherapy of Cancer","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:9263926","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9263926","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"J Immunother Cancer","raw_type":"Text"},{"id":"pmid:35798536","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35798536","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for immunotherapy of cancer","raw_type":"Journal Article"},{"id":"pmh:oai:serval.unil.ch:BIB_D204CE09BBCB","doi":null,"is_oa":true,"landing_page_url":"https://serval.unil.ch/notice/serval:BIB_D204CE09BBCB","pdf_url":null,"source":{"id":"https://openalex.org/S4306401797","display_name":"SERVAL (Universit\u00e9 de Lausanne)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210093590","host_organization_name":"Swiss School of Archaeology in Greece","host_organization_lineage":["https://openalex.org/I4210093590"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for immunotherapy of cancer, vol. 10, no. 7, pp. e004610","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:unige.ch:aou:unige:191782","doi":null,"is_oa":true,"landing_page_url":"https://archive-ouverte.unige.ch/unige:191782","pdf_url":null,"source":{"id":"https://openalex.org/S4306402259","display_name":"Archive ouverte UNIGE (University of Geneva)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I114457229","host_organization_name":"University of Geneva","host_organization_lineage":["https://openalex.org/I114457229"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for immunotherapy of cancer, vol. 10, no. 7 (2022) e004610","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:www.zora.uzh.ch:224125","doi":null,"is_oa":true,"landing_page_url":"https://www.zora.uzh.ch/id/eprint/224125/1/ZORA_e004610_full.pdf","pdf_url":"https://www.zora.uzh.ch/id/eprint/224125/1/ZORA_e004610_full.pdf","source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:iris.unil.ch:iris/192455","doi":null,"is_oa":true,"landing_page_url":"https://iris.unil.ch/handle/iris/192455","pdf_url":"https://iris.unil.ch/bitstreams/b51b5dd4-c26f-4356-a8a8-6db5171e61ee/download","source":{"id":"https://openalex.org/S7407055444","display_name":"IRIS","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"journal article"},{"id":"pmh:oai:doaj.org/article:21c29e95030742fcaad36b5414ae6fcf","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/21c29e95030742fcaad36b5414ae6fcf","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal for ImmunoTherapy of Cancer, Vol 10, Iss 7 (2022)","raw_type":"article"},{"id":"pmh:oai:www.zora.uzh.ch:20.500.14742/200260","doi":null,"is_oa":true,"landing_page_url":"https://www.zora.uzh.ch/handle/20.500.14742/200260","pdf_url":null,"source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Pires da Silva, I., Zakria, D., Ahmed, T., Trojanello, C., Dimitriou, F., Allayous, C., Gerard, C., Zimmer, L., Lo, S., Michielin, O., Lebbe, C., Mangana, J., Ascierto, P. A., Johnson, D. B., Carlino, M., Menzies, A., & Long, G. (2022). Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. Journal for ImmunoTherapy of Cancer, 10, e004610. https://doi.org/10.1136/jitc-2022-004610","raw_type":"Journal Article"},{"id":"doi:10.5167/uzh-224125","doi":"https://doi.org/10.5167/uzh-224125","is_oa":true,"landing_page_url":"https://doi.org/10.5167/uzh-224125","pdf_url":null,"source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"JournalArticle"}],"best_oa_location":{"id":"doi:10.1136/jitc-2022-004610","doi":"https://doi.org/10.1136/jitc-2022-004610","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-004610","pdf_url":"https://jitc.bmj.com/content/jitc/10/7/e004610.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for ImmunoTherapy of Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"},{"id":"https://openalex.org/F4320309577","display_name":"Array BioPharma","ror":"https://ror.org/018axtd57"},{"id":"https://openalex.org/F4320311600","display_name":"Regeneron Pharmaceuticals","ror":"https://ror.org/02f51rf24"},{"id":"https://openalex.org/F4320314128","display_name":"Les Laboratories Pierre Fabre","ror":"https://ror.org/04hdhz511"},{"id":"https://openalex.org/F4320317544","display_name":"Incyte","ror":"https://ror.org/00cvzzg84"},{"id":"https://openalex.org/F4320319515","display_name":"Seagen","ror":null},{"id":"https://openalex.org/F4320320966","display_name":"University of Sydney","ror":"https://ror.org/0384j8v12"},{"id":"https://openalex.org/F4320322148","display_name":"Eisai","ror":"https://ror.org/04vvh7p27"},{"id":"https://openalex.org/F4320328070","display_name":"Sun Pharma","ror":"https://ror.org/04vnqkx80"},{"id":"https://openalex.org/F4320328456","display_name":"Italfarmaco","ror":"https://ror.org/05xsppr58"},{"id":"https://openalex.org/F4320329041","display_name":"Melanoma Institute Australia","ror":"https://ror.org/02jxrhq31"},{"id":"https://openalex.org/F4320331537","display_name":"Qbiotics","ror":null},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"},{"id":"https://openalex.org/F4320332736","display_name":"Novartis Pharma","ror":"https://ror.org/0013shd50"},{"id":"https://openalex.org/F4320332932","display_name":"Merck Sharp and Dohme","ror":"https://ror.org/004nn4n27"},{"id":"https://openalex.org/F4320334705","display_name":"National Health and Medical Research Council","ror":"https://ror.org/011kf5r70"},{"id":"https://openalex.org/F4320338262","display_name":"Daiichi Sankyo Europe","ror":"https://ror.org/01qhj1g70"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4284669148.pdf","grobid_xml":"https://content.openalex.org/works/W4284669148.grobid-xml"},"referenced_works_count":41,"referenced_works":["https://openalex.org/W1834835434","https://openalex.org/W2019607817","https://openalex.org/W2084281756","https://openalex.org/W2104347254","https://openalex.org/W2120041024","https://openalex.org/W2128035403","https://openalex.org/W2152897456","https://openalex.org/W2156353875","https://openalex.org/W2222086386","https://openalex.org/W2316147013","https://openalex.org/W2332292689","https://openalex.org/W2527905628","https://openalex.org/W2529484692","https://openalex.org/W2560367415","https://openalex.org/W2572174216","https://openalex.org/W2606367731","https://openalex.org/W2607272476","https://openalex.org/W2753432434","https://openalex.org/W2794627893","https://openalex.org/W2888502795","https://openalex.org/W2903493423","https://openalex.org/W2925446385","https://openalex.org/W2947765148","https://openalex.org/W2951285627","https://openalex.org/W2978554061","https://openalex.org/W2978943095","https://openalex.org/W2990769829","https://openalex.org/W3017127491","https://openalex.org/W3043703771","https://openalex.org/W3048615803","https://openalex.org/W3087697977","https://openalex.org/W3132841322","https://openalex.org/W3153228158","https://openalex.org/W3159504492","https://openalex.org/W3163284774","https://openalex.org/W3174312474","https://openalex.org/W3182981660","https://openalex.org/W3196207248","https://openalex.org/W3201667898","https://openalex.org/W3202042792","https://openalex.org/W3217534140"],"related_works":["https://openalex.org/W3201979916","https://openalex.org/W3094969222","https://openalex.org/W3028730736","https://openalex.org/W7154938454","https://openalex.org/W2987654547","https://openalex.org/W4409145113","https://openalex.org/W2917811217","https://openalex.org/W7170152610","https://openalex.org/W2946610417","https://openalex.org/W2948884915"],"abstract_inverted_index":{"BACKGROUND:":[0],"Patients":[1,53],"with":[2,18,54,60,91,101,200,204,213,218,232,245,258,269,278,294,355],"V600BRAF":[3,55],"mutant":[4,56,97],"metastatic":[5,57,98],"melanoma":[6,58,99],"have":[7,325],"higher":[8,244,257],"rates":[9],"of":[10,43,105,160,178,237,284,289,312,344],"progression-free":[11],"survival":[12,16],"(PFS)":[13],"and":[14,41,82,122,133,146,171,253,274,276,287,310,321],"overall":[15],"(OS)":[17],"first-line":[19],"anti-PD1":[20],"(PD1]+anti-CTLA-4":[21],"(IPI)":[22],"versus":[23,45,66],"PD1.":[24],"Whether":[25],"this":[26],"is":[27,33,339],"also":[28],"true":[29],"after":[30,48,323,360],"BRAF/MEKi":[31,61,102,145,273,324],"therapy":[32],"unknown.":[34],"We":[35],"aimed":[36],"to":[37,112,194,358],"determine":[38],"the":[39,176,300,334],"efficacy":[40],"safety":[42,83],"PD1":[44,65,121,132,201,214,228,249,261,322],"IPI":[46],"+PD1":[47],"BRAF/MEK":[49],"inhibitors":[50],"(BRAF/MEKi).":[51],"METHODS:":[52],"treated":[59,100],"who":[62],"had":[63,119,125],"subsequent":[64,120],"IPI+PD1":[67,134,205,219,233,246,259,320,335,338],"at":[68,175],"eight":[69],"centers":[70],"were":[71,75,255],"included.":[72],"The":[73,235,282],"endpoints":[74],"objective":[76],"response":[77],"rate":[78,236],"(ORR),":[79],"PFS,":[80],"OS":[81,222,254,297],"in":[84,115,128,333],"each":[85],"group.":[86],"RESULTS:":[87],"Of":[88],"200":[89],"patients":[90,293],"V600E":[92],"(75%)":[93],"or":[94,240],"non-V600E":[95],"(25%)":[96],"(median":[103],"time":[104,143],"treatment":[106,109],"7.6":[107],"months;":[108,211,225],"cessation":[110],"due":[111],"progressive":[113],"disease":[114],"77%),":[116],"115":[117],"(57.5%)":[118],"85":[123],"(42.5%)":[124],"IPI+PD1.":[126],"Differences":[127],"patient":[129],"characteristics":[130],"between":[131,144,272],"groups":[135],"included,":[136],"age":[137],"(med.":[138],"63":[139],"vs":[140,149,163,169,181,202,215,229,248,260],"54":[141],"years),":[142],"PD1\u00b1IPI":[147,179,186],"(16":[148],"4":[150,241],"days),":[151],"Eastern":[152],"Cooperative":[153],"Oncology":[154],"Group":[155],"Performance":[156],"Status":[157],"(ECOG":[158],"PS)":[159],"\u22651":[161],"(62%":[162],"44%),":[164],"AJCC":[165],"M1C/M1D":[166],"stage":[167,279],"(72%":[168],"94%)":[170],"progressing":[172,307],"brain":[173,308],"metastases":[174,291,309,314],"start":[177,187],"(34%":[180],"57%).":[182],"Median":[183,207,221],"follow-up":[184],"from":[185],"was":[188,197,209,223,243],"37.8":[189],"months":[190,217,231],"(95%":[191],"CI,":[192],"33.9":[193],"52.9).":[195],"ORR":[196],"36%;":[198],"34%":[199],"39%":[203],"(p=0.5713).":[206],"PFS":[208,252],"3.4":[210,212],"3.6":[216],"(p=0.6951).":[220],"15.4":[224],"14.4":[226],"for":[227,266],"20.5":[230],"(p=0.2603).":[234],"grade":[238],"3":[239],"toxicities":[242],"(31%)":[247],"(7%).":[250],"ORR,":[251],"numerically":[256],"across":[262],"most":[263],"subgroups":[264],"except":[265],"females,":[267],"those":[268,277,354],"<10":[270],"days":[271],"PD1\u00b1IPI,":[275],"III/M1A/M1B":[280],"melanoma.":[281],"combination":[283,343],"ECOG":[285,304],"PS=0":[286],"absence":[288],"liver":[290],"identified":[292],">3":[295],"years":[296],"(area":[298],"under":[299],"curve,":[301],"AUC=0.74),":[302],"while":[303],"PS":[305],"\u22651,":[306],"presence":[311],"bone":[313],"predicted":[315],"primary":[316,356],"progression":[317],"(AUC=0.67).":[318],"CONCLUSIONS:":[319],"similar":[326],"outcomes":[327],"despite":[328],"worse":[329],"baseline":[330],"prognostic":[331],"features":[332],"group,":[336],"however,":[337],"more":[340],"toxic.":[341],"A":[342],"clinical":[345],"factors":[346],"can":[347],"identify":[348],"long-term":[349],"survivors,":[350],"but":[351],"less":[352],"accurately":[353],"resistance":[357],"immunotherapy":[359],"targeted":[361],"therapy.":[362]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2022-07-08T00:00:00"}